March 17 () - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by 40% in ...
About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...
Pfizer is betting on a new breast cancer drug combo that, in a key mid-stage trial, cut the risk of the disease worsening or patients dying by about 40% for a particularly tough-to-treat group.
Pfizer has a lofty goal for the CDK4 inhibitor atirmociclib, the New York pharma’s answer to Ibrance’s loss of patent protection next year. In 2025, Ibrance led Pfizer’s oncology portfolio with $1.04 ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results